Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia
Open accessAbstract
Background We developed a heterologous COVID-19 vaccine consisting of two components, a recombinant adenovirus type 26 (rAd26) vector and a recombinant adenovirus type 5 (rAd5) vector, both carrying the gene for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein (rAd26-S and rAd5-S). We aimed to assess the safety and immunogenicity of two formulations (frozen and lyophilised) of this vaccine. Methods We did two open, non-randomised phase 1/2 studies at two hospitals in Russia. We enrolled healthy adult volunteers (men and women) aged 18-60 years to both studies. In phase 1 of each study, we administered intramuscularly on day 0 either one dose of rAd26-S or one dose of rAd5-S and assessed the safety of the two components for 28 days. In phase 2 of the study, which began no earlier than 5 days after phase 1 vaccination, we administered intramuscularly a prime-boost vaccination, with rAd26-S given on day 0 and rAd5-S on day 21. Primary outcome measures were antigen-specific humoral immunity (SARS-CoV-2-specific antibodies measured by ELISA on days 0, 14, 21, 28, and 42) and safety (number of participants with adverse events monitored throughout the study). Secondary outcome measures were antigen-specific cellular immunity (T-cell responses and interferon-γ concentration) and change in neutralising antibodies (detected with a SARS-CoV-2 neutralisation assay). These trials are registered with ClinicalTrials.gov, NCT04436471 and NCT04437875. Findings Between June 18 and Aug 3, 2020, we enrolled 76 participants to the two studies (38 in each study). In each study, nine volunteers received rAd26-S in phase 1, nine received rAd5-S in phase 1, and 20 received rAd26-S and rAd5-S in phase 2. Both vaccine formulations were safe and well tolerated. The most common adverse events were pain at injection site (44 [58%]), hyperthermia (38 [50%]), headache (32 [42%]), asthenia (21 [28%]), and muscle and joint pain (18 [24%]). Most adverse events were mild and no serious adverse events were detected. All participants produced antibodies to SARS-CoV-2 glycoprotein. At day 42, receptor binding domain-specific IgG titres were 14 703 with the frozen formulation and 11 143 with the lyophilised formulation, and neutralising antibodies were 49·25 with the frozen formulation and 45·95 with the lyophilised formulation, with a seroconversion rate of 100%. Cell-mediated responses were detected in all participants at day 28, with median cell proliferation of 2·5% CD4+ and 1·3% CD8+ with the frozen formulation, and a median cell proliferation of 1·3% CD4+ and 1·1% CD8+ with the lyophilised formulation. Interpretation The heterologous rAd26 and rAd5 vector-based COVID-19 vaccine has a good safety profile and induced strong humoral and cellular immune responses in participants. Further investigation is needed of the effectiveness of this vaccine for prevention of COVID-19. Funding Ministry of Health of the Russian Federation.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In phase 1/2 trials, Gam-COVID-Vac had a good safety profile and produced strong humoral and cellular immune responses.
“A heterologous recombinant adenovirus (rAd)-based vaccine, Gam-COVID-Vac (Sputnik V), showed a good safety profile and induced strong humoral and cellular immune responses in participants in phase 1/2 clinical trials.”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,237 · cited 8× · see citing works
“28,31 In our study, we used a high dose of virus (100 TCID50) and a small amount of serum (50 µL serum and 50 µL of virus), whereas in studies of other vaccines, doses of 58–70 TCID50 and a larger amount of serum were used for analyses.”
BackgroundMethodInfluentialZhang, H., Penninger, J. M., Li, Y., Zhong, N., & Slutsky, A. S. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-05985-9 · Cited by 2,684 · see citing works
Folegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E. A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31604-4 · Cited by 2,419 · see citing works
Zhu, F.-C., Li, Y.-H., Guan, X.-H., Hou, L.-H., Wang, W.-J., Li, J.-X., Wu, S.-P., Wang, B.-S., Wang, Z., Wang, L., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31208-3 · Cited by 1,382 · see citing works
Xia, S., Liu, M., Wang, C., Xu, W., Lan, Q., Feng, S., Qi, F., Bao, L., Du, L., Liu, S., et al. (2020) · Cell Research · doi:10.1038/s41422-020-0305-x · Cited by 1,340 · see citing works
Zhu, F.-C., Guan, X.-H., Li, Y.-H., Huang, J.-Y., Jiang, T., Hou, L.-H., Li, J.-X., Yang, B.-F., Wang, L., Wang, W.-J., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31605-6 · Cited by 1,225 · see citing works
Astuti, I., & Ysrafil, Y. (2020) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2020.04.020 · Cited by 1,067 · see citing works
Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses
Jiang, S., Hillyer, C., & Du, L. (2020) · Trends in Immunology · doi:10.1016/j.it.2020.03.007 · Cited by 847 · see citing works
Structure analysis of the receptor binding of 2019-nCoV
Chen, Y., Guo, Y., Pan, Y., & Zhao, Z. J. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.02.071 · Cited by 806 · see citing works
Adenoviruses as vaccine vectors
Tatsis, N., & Ertl, H. C. J. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.07.013 · Cited by 669 · see citing works
New Vaccine Technologies to Combat Outbreak Situations
Rauch, S., Jasny, E., Schmidt, K. E., & Petsch, B. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01963 · Cited by 579 · see citing works
Adenovirus vectors for gene therapy, vaccination and cancer gene therapy
Wold, W., & Toth, K. (2014) · Current Gene Therapy · doi:10.2174/1566523213666131125095046 · Cited by 555 · see citing works
Heterologous prime-boost vaccination
Lu, S. (2009) · Current Opinion in Immunology · doi:10.1016/j.coi.2009.05.016 · Cited by 481 · see citing works
The First Approved Gene Therapy Product for Cancer Ad- p53 (Gendicine): 12 Years in the Clinic
Zhang, W., Li, L., Li, D., Liu, J., Li, X., Li, W., Xu, X., Zhang, M. J., Chandler, L. A., Lin, H., et al. (2018) · Human Gene Therapy · doi:10.1089/hum.2017.218 · Cited by 320 · see citing works
Sheridan, C. (2011) · Nature Biotechnology · doi:10.1038/nbt.1769 · Cited by 302 · see citing works
Adenoviral vectors for gene transfer and therapy
Volpers, C., & Kochanek, S. (2004) · The Journal of Gene Medicine · doi:10.1002/jgm.496 · Cited by 296 · see citing works
Datta, P., Liu, F.-M., Fischer, T., Rappaport, J., & Qin, X. (2020) · Theranostics · doi:10.7150/thno.48076 · Cited by 227 · see citing works
Mubarak, A., Alturaiki, W., & Hemida, M. G. (2019) · Journal of Immunology Research · doi:10.1155/2019/6491738 · Cited by 199 · see citing works
Memories that last forever: strategies for optimizing vaccine T-cell memory.
Ahlers, J., & Belyakov, I. (2010) · Blood · doi:10.1182/blood-2009-06-227546 · Cited by 165 · see citing works
Othman, H., Bouslama, Z., Brandenburg, J., da Rocha, J., Hamdi, Y., Ghedira, K., Srairi‐Abid, N., & Hazelhurst, S. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.05.028 · Cited by 141 · see citing works
Dolzhikova, I. V., Zubkova, O. V., Tukhvatulin, A. I., Dzharullaeva, A. S., Tukhvatulina, N. M., Shcheblyakov, D. V., Shmarov, M. M., Tokarskaya, E. A., Simakova, Y. V., Egorova, D. A., et al. (2017) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2016.1238535 · Cited by 132 · see citing works
Self-citationAdenoviral vector-based strategies against infectious disease and cancer
Zhang, C., & Zhou, D. (2016) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2016.1165908 · Cited by 110 · see citing works
Methods and clinical development of adenovirus-vectored vaccines against mucosal pathogens
Afkhami, S., Yao, Y., & Xing, Z. (2016) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2016.30 · Cited by 108 · see citing works
Immunological responses against SARS-coronavirus infection in humans.
XiaojunXu, & Xiao-MingGao (2004) · PubMed · Cited by 80 · see citing works
Immunoinformatic Analysis of T- and B-Cell Epitopes for SARS-CoV-2 Vaccine Design
Wang, D., Mai, J., Zhou, W., Yu, W., Zhan, Y., Wang, N., Epstein, N. D., & Yang, Y. (2020) · Vaccines · doi:10.3390/vaccines8030355 · Cited by 58 · see citing works
Dolzhikova, I. V., Tokarskaya, E. A., Dzharullaeva, A. S., et al. (2017) · Acta Naturae · doi:10.32607/20758251-2017-9-3-4-11 · Cited by 38 · see citing works
Self-citationTh1/Th2 cytokine responses following HIV-1 immunization in seronegative volunteers
THE AIDS VACCINE EVALUATION GROUP, Evans, T. G., Fitzgerald, T. F., Gibbons, D. C., Keefer, M. C., & Soucier, H. (1998) · Clinical & Experimental Immunology · doi:10.1046/j.1365-2249.1998.00486.x · Cited by 15 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
SARS-CoV-2 vaccines in development
Krammer, F. (2020) · Nature · doi:10.1038/s41586-020-2798-3 · Cited by 2,098 · see citing works
Logunov, D. Y., Dolzhikova, I. V., Shcheblyakov, D. V., Tukhvatulin, A. I., Zubkova, O. V., Dzharullaeva, A. S., Kovyrshina, A. V., Lubenets, N. L., Grousova, D. M., Erokhova, A. S., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00234-8 · Cited by 1,747 · see citing works
Self-citationRamasamy, M. N., Minassian, A. M., Ewer, K. J., Flaxman, A. L., Folegatti, P. M., Owens, D. R., Voysey, M., Aley, P. K., Angus, B., Babbage, G., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)32466-1 · Cited by 1,324 · see citing works
Immunological mechanisms of vaccine-induced protection against COVID-19 in humans
Sadarangani, M., Marchant, A., & Kollmann, T. R. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00578-z · Cited by 560 · see citing works
Novel approaches for vaccine development
Gebre, M. S., Brito, L. A., Tostanoski, L. H., Edwards, D. K., Carfi, A., & Barouch, D. H. (2021) · Cell · doi:10.1016/j.cell.2021.02.030 · Cited by 347 · see citing works
Hartley, G. E., Edwards, E. S. J., Aui, P. M., Varese, N., Stojanovic, S., McMahon, J., Peleg, A. Y., Boo, I., Drummer, H. E., Hogarth, P. M., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.abf8891 · Cited by 296 · see citing works
Accelerated COVID-19 vaccine development: milestones, lessons, and prospects
Bok, K., Sitar, S., Graham, B. S., & Mascola, J. R. (2021) · Immunity · doi:10.1016/j.immuni.2021.07.017 · Cited by 254 · see citing works
Adenovirus vector-based vaccine for infectious diseases
Sakurai, F., Tachibana, M., & Mizuguchi, H. (2022) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2021.100432 · Cited by 148 · see citing works
A comprehensive analysis of the efficacy and safety of COVID-19 vaccines
Cai, C., Peng, Y., Shen, E., Huang, Q., Chen, Y., Liu, P., Guo, C., Feng, Z., Gao, L., Zhang, X., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.08.001 · Cited by 146 · see citing works
Anti-science kills: from Soviet embrace of pseudoscience to accelerated attacks on US biomedicine.
Hotez, P. J. (2021) · PLOS Biology · doi:10.1371/journal.pbio.3001068 · Cited by 73 · see citing works
- Authors
- Logunov, D. Y., Dolzhikova, I. V., Zubkova, O. V., Tukhvatulin, A. I., Shcheblyakov, D. V., Dzharullaeva, A. S., Grousova, D. M., Erokhova, A. S., Kovyrshina, A. V., Botikov, A. G., Izhaeva, F. M., Popova, O., Ozharovskaya, T. A., Esmagambetov, I. B., Favorskaya, I. A., Zrelkin, D. I., Voronina, D. V., Shcherbinin, D. N., Semikhin, A. S., Simakova, Y. V., Tokarskaya, E. A., Lubenets, N. L., Egorova, D. A., Shmarov, M. M., Nikitenko, N. A., Morozova, L. F., Smolyarchuk, E. A., Kryukov, E. V., Babira, V. F., Borisevich, S. V., Naroditsky, B. S., & Gintsburg, A. L.
- Affiliations
- Gamalei Institute of Epidemiology and Microbiology (RU)
- Ministry of Health of the Russian Federation (RU)
- Ministry of Defence of the Russian Federation (RU)
- Corresponding author
- Logunov, Denis Y
- ORCID
- Logunov, Denis Y
- Dolzhikova, Inna V
- Zubkova, Olga V
- Shcheblyakov, Dmitry V
- Dzharullaeva, Alina S
- Grousova, Daria M
- Erokhova, Alina S
- Botikov, Andrei G
- Izhaeva, Fatima M
- Popova, Olga
- Esmagambetov, Ilias B
- Favorskaya, Irina A
- Voronina, Daria V
- Semikhin, Alexander S
- Simakova, Yana V
- Lubenets, Nadezhda L
- Egorova, Daria A
- Nikitenko, Natalia A
- Borisevich, Sergei V
- Naroditsky, Boris S
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2020-09
- Volume
- 396
- Issue
- 10255
- Pages
- 887-897
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- PMC
- PMC7471804
- OpenAlex
- W3083750089
- Cited by
- 1,055
- References
- 27
- Citations by year
- 2026: 13 · 2025: 37 · 2024: 71 · 2023: 97 · 2022: 229 · 2021: 499 · 2020: 107
- FWCI
- 30.61
- Type
- journal article
- Language
- en
- Update notices
- erratum (2021-01-09)
- Open access
- bronze
- doi.org
- Locations
- The Lancet (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Ministry of Education and Science of the Russian Federation (056-00034-20-02)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Keywords
- COVID-19 vaccines, SARS-CoV-2 spike protein, heterologous prime-boost, recombinant adenovirus vector, vaccine safety, immunogenicity, humoral immunity, cell-mediated immunity, T cell response, interferon-gamma, neutralizing antibodies
- MeSH terms
- Betacoronavirus, COVID-19, SARS-CoV-2, COVID-19 Vaccines, Adenoviridae, Adult, Antibodies, Viral, Female, Humans, Immunoglobulin G, Immunity, Cellular, Immunization, Secondary, Injections, Intramuscular, Male, Pneumonia, Viral, Russia, Viral Vaccines, Coronavirus Infections, Young Adult, Immunity, Humoral, Antibodies, Neutralizing, Pandemics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
